ClinicalTrials.gg
CompletedNCT05560464Updated Mar 20, 2024

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment

A Phase 1 interventional study of VX-548 in Pain, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-20.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jul 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing suzetrigine in Pain — 4 open to participants now, 4 under way, 2 of them phase 3. suzetrigine · Pain.

Enrollment
15th of 21
36 · median 50
Started
2022
with 3 others
Phase 1
15 of 21
none open now
Registered
3rd of 21
by date
Lead sponsor
15 of 21
Vertex Pharmaceuticals Incorporated

Among the 21 studies testing suzetrigine in Pain, this one is the 15th largest by enrollment, is one of 4 that started in 2022, is one of 15 in phase 1, and was the 3rd registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 21 studies testing suzetrigine in Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About suzetrigine

suzetrigine: first FDA approval 2025 (JOURNAVX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing suzetrigine in Pain, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the pharmacokinetics and safety of multiple doses of VX-584 in participants with mild or moderate hepatic impairment as compared to matched healthy controls.

Read the detailed description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4) (A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Cohorts 1 and 3: Participants with Mild or Moderate Hepatic Impairment

    • Participants will satisfy the criteria for mild (Cohort 1) and moderate hepatic impairment (Cohort 3) defined as a total score of 5 to 6 and 7 to 9 points, respectively at the screening visit
    • Participants will have chronic (greater than or equal to (≥) 6 months) documented liver disease
  • Cohorts 2 and 4: Matched Healthy Participants

    • Participants will be matched (cohort 2 matched to cohort 1; and cohort 4 matched to cohort 3) during screening to participants with hepatic impairment for age, sex, and weight

Key Exclusion Criteria:

  • Cohorts 1 and 3: Participants with Mild or Moderate Hepatic Impairment

    • History of febrile illness or other acute illness that has not fully resolved by 14 days before the first dose of study drug
    • Severe portal hypertension
    • History or presence of severe hepatic encephalopathy (Grade >2)
    • Any condition possibly affecting drug absorption
    • Significant renal dysfunction ( \<60 milliliter per minute [mL/min] ) estimated according to the method of Cockcroft and Gault at the screening Visit or Day-1
    • History of solid organ or bone marrow transplantation
  • Cohorts 2 and 4: Matched Healthy Participants

    • History of febrile illness or other acute illness that has not fully resolved by 14 days before the first dose of study drug
    • Any condition possibly affecting drug absorption

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Cohort 1: Mild Hepatic Impairment

    Participants will receive multiple doses of VX-548 every 12 hours (q12h) from Day 1 through Day 14.

    Drug: VX-548

  • Experimental
    Cohort 2: Matched Healthy Participants

    Healthy participants matched to cohort 1 will receive multiple doses of VX-548 q12h from Day 1 through Day 14.

    Drug: VX-548

  • Experimental
    Cohort 3: Moderate Hepatic Impairment

    Participants will receive multiple doses of VX-548 q12h from Day 1 through Day 14.

    Drug: VX-548

  • Experimental
    Cohort 4: Matched Healthy Participants

    Healthy participants matched to cohort 3 will receive multiple doses of VX-548 q12h from Day 1 through Day 14.

    Drug: VX-548

Interventions

  • DrugVX-548

    Tablets for oral administration.

    Also known as: Suzetrigine

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of VX-548

    Time frame: Day 1 to Day 31

  2. Area Under the Plasma Concentration Versus Time Curve During a Dosing Interval (AUCtau) of VX-548

    Time frame: Day 1 to Day 31

  3. Time Taken for VX-548 to Reach Maximum Concentration (tmax)

    Time frame: Day 1 to Day 31

  4. Time Required for Plasma Concentration of VX-548 to Reduce to Half (t1/2)

    Time frame: Day 1 to Day 31

  5. Apparent Volume of Distribution of VX-548 (Vz/F)

    Time frame: Day 1 to Day 31

  6. Apparent Clearance of VX-548 (CL/F)

    Time frame: Day 1 to Day 31

  7. Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to the Last Measured Concentration (AUC0-last) of VX-548

    Time frame: Day 1 to Day 31

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of VX-548 Metabolite

    Time frame: Day 1 to Day 31

  2. Area Under the Plasma Concentration Versus Time Curve During a Dosing Interval (AUCtau) of VX-548 Metabolite

    Time frame: Day 1 to Day 31

  3. Time Taken for VX-548 metabolite to Reach Maximum Concentration (tmax)

    Time frame: Day 1 to Day 31

  4. Time Required for Plasma Concentration of VX-548 Metabolite to Reduce to Half (t1/2)

    Time frame: Day 1 to Day 31

  5. Apparent Volume of Distribution of VX-548 Metabolite (Vz/F)

    Time frame: Day 1 to Day 31

  6. Apparent Clearance of VX-548 Metabolite (CL/F)

    Time frame: Day 1 to Day 31

  7. Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to the Last Measured Concentration (AUC0-last) of VX-548 Metabolite

    Time frame: Day 1 to Day 31

  8. Fraction Unbound (fu) for VX-548 and its Metabolite in Plasma

    Time frame: Day 14: Up to 24 hours Post-dose

  9. Unbound Area Under the Concentration Versus Time Curve of VX-548 and its Metabolite

    Time frame: Day 14: Up to 24 hours Post-dose

  10. Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Day 42

07

Study locations

2 sites
  • Division of Clinical Pharmacology, University of Miami
    Miami, Florida 33136, United States
  • Orlando Clinical Research Center
    Orlando, Oklahoma 32809, United States
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Jul 2023, 9 months.

Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 9 months is above that.

Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2022
First posted
Sep 29, 2022
StartActual
Oct 14, 2022
Primary completionActual
Jul 24, 2023
CompletionActual
Jul 24, 2023
Last update
Mar 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05560464
Responsible party
Sponsor
First posted
Sep 29, 2022
Start date
Oct 14, 2022
Primary completion
Jul 24, 2023
Completion
Jul 24, 2023
Last update
Mar 20, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suzetrigine

Start the discussion